In this video health care analysts David Williamson and Max Macaluso discuss Pfizer's just-released third-quarter earnings. David distills the highlights and hits on all of the critical takeaways for investors, including potential blockbuster Eliquis shared with Bristol-Myers Squibb and the "bapi" Alzheimer's failure, which it shares with Elan. Watch and discover everything you need to know about Pfizer's most recent quarter.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Pfizer Earnings: Critical Takeaways
By Dave Williamson
–
Nov 1, 2012 at 5:18PM
NYSE: PFE
Pfizer
Market Cap
$143B
Today's Change
(-1.33%) -$0.34
Current Price
$25.23
Price as of December 11, 2024, 4:00 p.m. ET
Everything you need to know in 1 short video.
David Williamson owns shares of Pfizer. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Elan. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles
Want an Extra $1,000 of Dividend Income in 2025? Invest $11,400 in These 3 High-Yield Stocks.
Got $5,000? These 3 Growth Stocks Are Bargain Buys Right Now.
3 Magnificent Dividend Stocks With Yields Above 6% to Buy in December
Is This a New Reason to Buy Pfizer Stock Hand Over Fist?
Is Pfizer Stock in Trouble?
916%
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.